Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
ERNA Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: June 08, 2026
Report Source: 2026 1st Quarter Report
Ernexa Therapeutics Inc. Stock Analysis ERNA
United States Health Care Nano Cap Report: Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 5 full-time employees. The firm is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The firm seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The firm is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.
Read More Ernexa Therapeutics Inc (ERNA) Chart
Key Statistics of Ernexa Therapeutics Inc (ERNA)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$6.13Volume
32.35KP/E Ratio (TTM)
-52 Week Range
Market Cap
14.53MAvg. Volume
63.18KDividend Yield
0.28%Financial Metrics & Statements of Ernexa Therapeutics Inc (ERNA)
FAQ's for Ernexa Therapeutics Inc (ERNA)
- According to Musaffa’s Shariah screening methodology, Ernexa Therapeutics Inc (ERNA) is currently classified as NOT HALAL as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Ernexa Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Ernexa Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Ernexa Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Ernexa Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Ernexa Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.